Extinktion

Extinktion is a Munich-based biotechnology company specializing in the development of next-generation "armored" CAR-T cell therapies for the treatment of solid tumors. Spun out from the Ludwig-Maximilians-Universität (LMU) Munich, the company utilizes a proprietary engineering platform to make T cells resistant to the immunosuppressive signals prevalent in the tumor microenvironment. Their lead technology focuses on genetic modifications that counteract inhibitory cytokines, such as TGF-beta, which typically limit the efficacy of adoptive cell transfers in solid cancers. By enhancing the persistence and functionality of T cells within hostile tumor tissues, Extinktion aims to provide curative options for patients with difficult-to-treat oncological indications.